ABBVIE
- Country
- π«π·France
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 341
- Registration Number
- NCT03978520
- Locations
- πΊπΈ
Medvin Clinical Research /ID# 211996, Tujunga, California, United States
πΊπΈArizona Arthritis & Rheumatology Research, PLLC /ID# 214522, Mesa, Arizona, United States
π¨π³Shanghai Changhai Hospital /ID# 211819, Shanghai, Shanghai, China
A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: ABBV-3067Drug: Placebo ABBV-3067Drug: Placebo ABBV-2222Drug: ABBV-2222
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 78
- Registration Number
- NCT03969888
- Locations
- πΈπ°
Univerzitna nemocnica Bratislava Nemocnica Ruzinov /ID# 213596, Bratislava, Slovakia
π«π·AP-HP - Hopital Cochin /ID# 212864, Paris, France
πΊπΈMedical University of South Carolina /ID# 212187, Charleston, South Carolina, United States
Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 118
- Registration Number
- NCT03951077
- Locations
- πΊπΈ
Thomas Jefferson University /ID# 205614, Philadelphia, Pennsylvania, United States
πΊπΈUniversity of Texas (UT) Health Women's Research Center at Memorial City /ID# 216266, Houston, Texas, United States
πΊπΈAdvances in Health, Inc. /ID# 211249, Houston, Texas, United States
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
- Conditions
- Acute Myeloid Leukemia (AML)Cancer
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT03941964
- Locations
- πΊπΈ
Rocky Mountain Cancer Centers /ID# 211508, Lone Tree, Colorado, United States
πΊπΈTennessee Oncology - Chattanooga / McCallie /ID# 212717, Chattanooga, Tennessee, United States
πΊπΈPrisma Health Cancer Inst - Eastside /ID# 211466, Greenville, South Carolina, United States
A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 243
- Registration Number
- NCT03926169
- Locations
- π«π·
HCL - Hopital Edouard Herriot /ID# 218408, Lyon, France
πΊπΈMinnesota Clinical Study Center /ID# 211979, New Brighton, Minnesota, United States
πΊπΈBurke Pharmaceutical Research /ID# 211671, Hot Springs, Arkansas, United States
Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea
- Conditions
- Psoriasis
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 2
- Registration Number
- NCT03925441
- Locations
- π°π·
Ajou University Hospital /ID# 207843, Suwon-si, Gyeonggido, Korea, Republic of
A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
- Conditions
- Anxiety Disorders,Generalized Anxiety Disorder
- Interventions
- Drug: EscitalopramOther: Placebo
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 273
- Registration Number
- NCT03924323
- Locations
- πΊπΈ
UH Cleveland Medical Center /ID# 233373, Cleveland, Ohio, United States
πΊπΈCenter for Psychiatry and Behavioral Medicine Inc /ID# 233355, Las Vegas, Nevada, United States
πΊπΈATP Clinical Research, Inc /ID# 233362, Costa Mesa, California, United States
A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT03924947
- Locations
- πΊπΈ
Virginia Commonwealth University Medical Center Main Hospital /ID# 164574, Richmond, Virginia, United States
πΊπΈNationwide Children's Hospital /ID# 225628, Columbus, Ohio, United States
πΊπΈUniversity of Iowa Hospitals and Clinics /ID# 164551, Iowa City, Iowa, United States
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: ABBV-157Drug: Placebo for ABBV-157
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 65
- Registration Number
- NCT03922607
- Locations
- πΊπΈ
Total Skin and Beauty Derm Ctr /ID# 222593, Birmingham, Alabama, United States
πΊπΈAnaheim Clinical Trials LLC /ID# 213645, Anaheim, California, United States
πΊπΈDermatology Res. Assoc., CA /ID# 224980, Los Angeles, California, United States
Expanded Access to Risankizumab
- Conditions
- Crohn's DiseaseUlcerative Colitis (UC)
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03914261